about-us

History

History

Alder received initial funding from the United States Army in 2004 to explore development of new production technologies for humanized antibodies. Since then, Alder has focused on developing its pipeline of therapeutic candidates that leverage its proprietary monoclonal antibody discovery and manufacturing technologies to address a variety of unmet medical needs.

2016

March – Positive topline data announced from ALD403 Phase 2b study in patients with chronic migraine

April – Alder completed follow-on offering raising approximately $134.6 million

May – Alder licenses the rights to clazakizumab to Vitaeris

June – Positive 24-week data announced from ALD403 Ph2b study in patients with chronic migraine

November – Initiation of PROMISE 2 Pivotal Trial of Eptinezumab (formerly ALD403) in patients with chronic migraine

2015

January – Alder completes follow-on offering raising approximately $191 million

June – Second follow-on offering completed, raising approximately $216 million

October – Initiation of pivotal trial of ALD403 in frequent episodic migraine

2014

May – Clinical trial data for ALD403 in migraine presented at American Academy of Neurology

May – Alder completes IPO and trades under the symbol ‘ALDR’ on the NASDAQ stock market

November – ALD403 Phase IIb clinical trial for chronic migraine initiated

2013

March – First patients dosed with ALD403 in Phase II proof-of-concept clinical trial for treatment of frequent episodic migraine

October – Clazakizumab (ALD518) RA Phase IIb data presented at American College of Rheumatology

2012

April – Series D financing completed

May – ALD403 Phase I clinical trial initiated for the treatment of migraine

2011

June – ALD518 Phase IIb clinical trial in RA initiated; Alder receives $15M milestone payment from Bristol-Myers Squibb

2010

November – Data from multiple studies of ALD518 presented at American College of Rheumatology

2009

November – Alder and Bristol-Myers Squibb enter global agreement for the development and commercialization of ALD518

2008

January – Series C financing completed

October – ALD518 Phase II clinical trials initiated for Rheumatoid Arthritis (RA) and Non Small Cell Lung Cancer (NSCLC)

2007

November – Initial clinical trial of ALD518 in healthy volunteers

2006

July – Series B financing completed

2005

August – Series A financing completed

October – Collaborative alliance formed with Schering-Plough to identify and manufacture antibody therapeutics

November – Collaborative alliance formed with Seattle Genetics

2004

January – Alder incorporated

October – Army STTR funding awarded for development of new production technologies for humanized antibodies

November – Seed capital funding completed

Menu
×